Perinatal Morbidity
Perinatal Morbidity - Related Videos
08:47
The Hypoxic Ischemic Encephalopathy Model of Perinatal Ischemia
0 Views •
Cited by 48 •
2008
The postnatal rat model for hypoxic-ischemic brain injury is a well-established model of human neonatal hypoxic ischemic encephalopathy (HIE). In this article, we describe the model of HIE in post-natal rat pups.
10:57
Using In Vivo and Tissue and Cell Explant Approaches to Study the Morphogenesis and Pathogenesis of the Embryonic and Perinatal Aorta
0 Views •
2017
Protocols for studying the embryonic and perinatal murine aorta using in vivo clonal analysis and fate mapping, aortic explants, and isolated smooth muscle cells are detailed here. These diverse approaches facilitate the investigation of the morphogenesis of the embryonic and perinatal aorta in normal development and the pathogenesis in disease.
04:36
Noninvasive Electrocardiography in the Perinatal Mouse
0 Views •
Cited by 3 •
2020
Here, we present a noninvasive electrocardiography (ECG) protocol, optimized for early postnatal mice, that does not require the use of anesthetics.
12:31
In Vivo Modeling of the Morbid Human Genome using Danio rerio
0 Views •
Cited by 66 •
2013
Here, we present a systematic approach for developing physiologically relevant, sensitive and specific in vivo assays for interpreting variation in human pathology. Transient genetic manipulation via microinjection of WT and mutant human mRNA and morpholino (MO) antisense oligonucleotides harness the tractability of the developing zebrafish embryo to rapidly assay pathogenic mutations, especially, but not exclusively, in the context of human developmental disorders.
04:18
Modeling Ascending Vaginal Infection, Preterm Birth, and Neonatal Morbidity in Mice
0 Views •
2025
Preterm birth (delivery < 37 weeks) is an urgent global health issue with suboptimal prevention and treatment options. We present a mouse model of ascending vaginal bacterial infection-induced preterm birth and outline how to analyze the resulting neonatal morbidity and mortality.
FAQs
Placental barrier function helps determine whether a pathogen or infection-related signal reaches the fetus. When this protective interface does not prevent transmission or inflammatory effects, fetal health may be affected even before delivery. This mechanism connects maternal infection with outcomes such as fetal growth restriction, preterm birth, and possible later developmental harm.
Maternal antibody transfer provides the developing fetus and newborn with immune protection before their own defenses are fully established. The effectiveness of this protection depends on transfer across the placenta and the infant’s developmental stage. Understanding this relationship helps explain why maternal immunization strategies can contribute to reducing infection-related complications around birth.
A newborn’s developing immune defenses may respond less effectively to infectious threats than a mature immune system. This immaturity can influence how rapidly infection is controlled and how severe illness becomes. At the same time, infection-driven inflammation may injure tissues, helping explain the risk of neonatal sepsis and other serious complications.
Perinatal complications may result from the inflammatory response as well as from direct pathogen transmission. Infection-driven inflammation can affect the placenta, fetus, or newborn and may contribute to impaired health during this vulnerable period. This distinction is important because disease severity reflects both exposure to the pathogen and the biological consequences of inflammation.
Maternal pathogens can affect the fetus by crossing the placenta, creating a pathway for exposure before birth. They may also reach the infant during delivery, producing a different timing of exposure around birth. Recognizing these routes supports the selection of maternal and neonatal screening, preventive measures, and timely treatment strategies.
Maternal and neonatal screening can identify infection-related risks, while vaccination strategies aim to reduce preventable exposure and support protective maternal antibody transfer. When illness or risk is identified, timely treatment can limit complications affecting the mother, fetus, or newborn. Together, these approaches connect immunological understanding with practical infection prevention and care.
Researchers and clinicians may assess outcomes including fetal growth restriction, preterm birth, neonatal sepsis, and long-term developmental harm. These outcomes capture effects occurring before birth, around delivery, and after birth rather than focusing only on immediate infection. Comparing them helps clarify how placental protection, immune development, antibody transfer, and inflammation shape disease severity.